Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a <i>Diabetes Care</i> Editors' Expert Forum.

Diabetes Care · 2018 · PMC5741160 · PMID 29263194

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Regarding safety, the increased risk of HF hospitalization with saxagliptin in SAVOR-TIMI 53 ( 6 ) and a nonsignificant trend with aloglipitin in EXAMINE ( 7 , 59 ) resulted in the addition of new safety warnings to the labels of those medications ( 64 ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.